This company has been acquired
Abiomed Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Información clave
5.2%
Tasa de crecimiento de los beneficios
4.7%
Tasa de crecimiento del BPA
Crecimiento de la industria Medical Equipment | 8.9% |
Tasa de crecimiento de los ingresos | 12.3% |
Rentabilidad financiera | 17.3% |
Margen neto | 24.8% |
Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Abiomed (NASDAQ:ABMD) Has More To Do To Multiply In Value Going Forward
Oct 24Abiomed's Impella low profile sheath gets FDA clearance
Oct 17Abiomed: Correction Offers Good Buying Opportunity
Sep 28U.S. FDA gives two approvals to Abiomed Impella heart pumps
Sep 16What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?
Sep 13Abiomed FQ1 2023 Earnings Preview
Aug 03Returns On Capital At Abiomed (NASDAQ:ABMD) Have Stalled
Jul 11Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages
May 17Is Abiomed (NASDAQ:ABMD) A Risky Investment?
Mar 17Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk
Jan 24The Returns At Abiomed (NASDAQ:ABMD) Aren't Growing
Jan 04These 4 Measures Indicate That Abiomed (NASDAQ:ABMD) Is Using Debt Safely
Dec 14Abiomed: Impella Will Continue To Drive Revenue Growth
Sep 10Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return
Sep 01Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating
Jul 13At US$335, Is It Time To Put Abiomed, Inc. (NASDAQ:ABMD) On Your Watch List?
Jul 08DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue
Jun 08Abiomed acquires preCARDIA a company targeting acute heart failure
Jun 01Here's Why I Think Abiomed (NASDAQ:ABMD) Might Deserve Your Attention Today
May 16Boston Scientific’s new clinical trial can impact Abiomed: Raymond James
May 06Abiomed FQ4 2021 Earnings Preview
Apr 28Should You Investigate Abiomed, Inc. (NASDAQ:ABMD) At US$315?
Apr 02Abiomed, Inc.'s (NASDAQ:ABMD) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 12Has Abiomed (NASDAQ:ABMD) Got What It Takes To Become A Multi-Bagger?
Feb 18Results: Abiomed, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Jan 31Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Abiomed. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Sep 22 | 1,074 | 267 | 452 | 175 |
30 Jun 22 | 1,056 | 218 | 438 | 171 |
31 Mar 22 | 1,032 | 137 | 423 | 164 |
31 Dec 21 | 1,003 | 133 | 413 | 153 |
30 Sep 21 | 974 | 149 | 392 | 143 |
30 Jun 21 | 935 | 154 | 368 | 131 |
31 Mar 21 | 848 | 226 | 333 | 119 |
31 Dec 20 | 813 | 200 | 318 | 114 |
30 Sep 20 | 803 | 208 | 317 | 107 |
30 Jun 20 | 798 | 159 | 324 | 101 |
31 Mar 20 | 841 | 203 | 342 | 99 |
31 Dec 19 | 841 | 245 | 339 | 99 |
30 Sep 19 | 820 | 221 | 334 | 98 |
30 Jun 19 | 797 | 258 | 326 | 96 |
31 Mar 19 | 769 | 259 | 322 | 94 |
31 Dec 18 | 737 | 222 | 316 | 89 |
30 Sep 18 | 690 | 190 | 302 | 82 |
30 Jun 18 | 641 | 165 | 283 | 79 |
31 Mar 18 | 594 | 112 | 263 | 74 |
31 Dec 17 | 544 | 90 | 247 | 68 |
30 Sep 17 | 505 | 92 | 235 | 67 |
30 Jun 17 | 475 | 77 | 228 | 66 |
31 Mar 17 | 445 | 52 | 218 | 65 |
31 Dec 16 | 415 | 48 | 203 | 64 |
30 Sep 16 | 386 | 43 | 191 | 61 |
30 Jun 16 | 359 | 42 | 178 | 54 |
31 Mar 16 | 330 | 38 | 164 | 49 |
31 Dec 15 | 303 | 126 | 152 | 44 |
Ingresos de calidad: ABMD has a large one-off gain of $61.8M impacting its September 30 2022 financial results.
Margen de beneficios creciente: ABMD's current net profit margins (24.8%) are higher than last year (15.3%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ABMD's earnings have grown by 5.2% per year over the past 5 years.
Acelerando crecimiento: ABMD's earnings growth over the past year (78.9%) exceeds its 5-year average (5.2% per year).
Beneficios vs. Industria: ABMD earnings growth over the past year (78.9%) exceeded the Medical Equipment industry -8.4%.
Rentabilidad financiera
Alta ROE: ABMD's Return on Equity (17.3%) is considered low.